STAAR SURGICAL CO - 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for STAAR SURGICAL CO for the period ended September 27, 1996. The company manufactures and sells intraocular lenses (IOLs) and related ophthalmic products. As of November 6, 1996, there were 13,044,228 shares of common stock outstanding.
Key Financial Metrics (Nine Months Ended Sept 27, 1996)
- Revenue: $30,655,147 (Sales: $29,905,147; Royalties: $750,000).
- Gross Profit: $23,304,309 (Gross Margin: 76.0%).
- Operating Income: $7,336,096.
- Net Income: $5,018,120 (EPS: $0.36).
- Cash Flow: Net cash provided by operating activities was $6,559,366. Net cash used in investing activities was $(8,239,456), primarily due to capital expenditures and patent acquisitions. Net cash provided by financing activities was $4,499,603.
- Liquidity: Cash and cash equivalents totaled $6,586,524. Current ratio was 2.1:1 with net working capital of $15.4 million.
- Debt: Total debt (current and long-term) was approximately $8.4 million ($7.39M notes payable + $0.64M current portion of long-term debt + $0.97M long-term debt).
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 24.0% compared to the nine months ended September 29, 1995. International sales rose 54.4%, while U.S. sales increased 11.1%.
- Profitability: Net income decreased 9.2% to $5.0 million from $5.5 million in the prior year period, despite higher revenues. This was driven by a significant increase in the income tax provision (from 0.7% to 7.9% of revenue) due to the utilization of deferred tax assets.
- Expenses: Operating expenses increased 19.2%. Research and Development (R&D) expenses rose 28.4% to $2.9 million. Marketing and selling expenses increased 17.8% but decreased as a percentage of revenue (30.7% to 29.1%).
- Balance Sheet: Inventories increased from $9.6 million to $12.5 million in anticipation of future sales. Patents and licenses increased significantly from $3.5 million to $8.4 million due to $5.3 million in capitalized additions.
Outlook, Risks, and Management Commentary
- Outlook: Management expects profitability to continue. Capital expenditures for the next twelve months are expected to decrease from 1996 levels. Marketing and selling expenses are expected to increase in 1997 with the rollout of four new product lines internationally.
- Product Strategy: Growth is driven by foldable IOLs (ELASTIMIDE) and new products like the Glaucoma Wick and implantable contact lens (ICL).
- Risks: International operations expose the company to exchange rate fluctuations, foreign government regulations, and political instability. The company is involved in ongoing litigation to protect its patents and proprietary technology.
- Contingencies: Litigation with Alcon and Allergan was settled during 1996.
- Tax Status: The company has remaining net operating loss carryforwards and will not pay Federal income taxes until these are fully utilized.
Investor Verification Checklist
- Verify the sustainability of the 54.4% growth in international sales and the impact of exchange rates on future margins.
- Confirm the timeline for the commercialization of new products (Glaucoma Wick, ICL) and their contribution to 1997 revenue.
- Monitor the utilization of net operating loss carryforwards and the resulting effective tax rate in future quarters.
- Assess the impact of increased inventory levels ($12.5M) on future working capital requirements and potential obsolescence.
- Review the status of ongoing patent litigation and the $5.3M spent on patent acquisition and defense.